Combination Experience of Ixazomib, Lenalidomide, Dexamethasone in Relapsed Refractory Multiple Myeloma: Real-Life Data

Tuba Ersal; Vildan Ozkocaman; Cumali Yalçın; Bedrettin Orhan; Ömer Candar; Sinem Çubukçu; Tuba Güllü Koca; Fazıl Cagrı Hunutlu; Şeyma Yavuz; İbrahim Ethem Pınar; Rıdvan Ali; Fahir Özkalemkaş

Makale detayları

Combination Experience of Ixazomib, Lenalidomide, Dexamethasone in Relapsed Refractory Multiple Myeloma: Real-Life Data

Yazarlar:

Tuba Ersal | Vildan Ozkocaman | Cumali Yalçın | Bedrettin Orhan | Ömer Candar | Sinem Çubukçu | Tuba Güllü Koca | Fazıl Cagrı Hunutlu | Şeyma Yavuz | İbrahim Ethem Pınar | Rıdvan Ali | Fahir Özkalemkaş

Yayıncı:

Bursa Uludağ University

Ana Başlıklar:

Hematoloji

Dergi:

Uludağ Üniversitesi Tıp Fakültesi Dergisi Vol.49 Issue 1, pp.95-99

Belge Tipi:

Makale

Yayın Tarihi:

9/2023

Belge Dili:

Türkçe

Document ID (Org No.):

2001291066

pISSN:

1300-414X

Anahtar kelimeler:

Özet:

 Ixazomib, the first oral proteasome inhibitor PI, is approved for treating relapsed refractory multiple myeloma RRMM in combination with lenalidomide and dexamethasone. However, clinical trial results do not always match real-world results. This study aimed to evaluate the results of ixazomib-based combination therapy for the treatment of patients with RRMM in real life. A total of 45 patients with RRMM from the Bursa Uludağ University Faculty of Medicine Department of Hematology were included in the study retrospectively. The median follow-up time was 15.9 months. The median age was 66 40-84. 8.8 of patients were ranked 2nd, 15.5 were ranked 3rd, 35.5 were ranked 4th, and 40 were 5th took ixazomib. Overall, 100 of patients were on PIs bortezomib 100, carfilzomib 31.1, 88.8 on immunomodulatory drugs IMID lenalidomide 86.6, pomalidomide 33.3, thalidomide 4.4 and 55.5 also underwent autologous stem cell transplantation before the combination of ixazomib, lenalidomide, and dexamethasone IRd. All patients received ixazomib in combination with lenalidomide and dexamethasone. The treatment was well tolerated, with a low discontinuation rate due to adverse events 6.6. The most common side effects were cytopenia 50 and infection 25. The overall response rate was 77.7, the very good partial response rate was 20, the complete response rate was 28, the partial response rate was 11.4, the minimal response rate was 5.7, the stable disease rate was 5.7, and progressive disease rate was 28.5. Median progression-free survival PFS on ixazomib treatment was 29.1 months 95 CI 17.2-40.9. PFS was 75 and 59 at 12 and 24 months, respectively. Median overall survival OS was 22.6 months 95 CI 18.8-30.3.; OS was 73 and 49 at 12 and 24 months, respectively. IRd is an effective, safe, and easy-to-administer regimen in real-life RRMM patients because it can be administered orally.

 Ixazomib, the first oral proteasome inhibitor PI, is approved for treating relapsed refractory multiple myeloma RRMM in combination with lenalidomide and dexamethasone. However, clinical trial results do not always match real-world results. This study aimed to evaluate the results of ixazomib-based combination therapy for the treatment of patients with RRMM in real life. A total of 45 patients with RRMM from the Bursa Uludağ University Faculty of Medicine Department of Hematology were included in the study retrospectively. The median follow-up time was 15.9 months. The median age was 66 40-84. 8.8 of patients were ranked 2nd, 15.5 were ranked 3rd, 35.5 were ranked 4th, and 40 were 5th took ixazomib. Overall, 100 of patients were on PIs bortezomib 100, carfilzomib 31.1, 88.8 on immunomodulatory drugs IMID lenalidomide 86.6, pomalidomide 33.3, thalidomide 4.4 and 55.5 also underwent autologous stem cell transplantation before the combination of ixazomib, lenalidomide, and dexamethasone IRd. All patients received ixazomib in combination with lenalidomide and dexamethasone. The treatment was well tolerated, with a low discontinuation rate due to adverse events 6.6. The most common side effects were cytopenia 50 and infection 25. The overall response rate was 77.7, the very good partial response rate was 20, the complete response rate was 28, the partial response rate was 11.4, the minimal response rate was 5.7, the stable disease rate was 5.7, and progressive disease rate was 28.5. Median progression-free survival PFS on ixazomib treatment was 29.1 months 95 CI 17.2-40.9. PFS was 75 and 59 at 12 and 24 months, respectively. Median overall survival OS was 22.6 months 95 CI 18.8-30.3.; OS was 73 and 49 at 12 and 24 months, respectively. IRd is an effective, safe, and easy-to-administer regimen in real-life RRMM patients because it can be administered orally.

 Ixazomib, the first oral proteasome inhibitor PI, is approved for treating relapsed refractory multiple myeloma RRMM in combination with lenalidomide and dexamethasone. However, clinical trial results do not always match real-world results. This study aimed to evaluate the results of ixazomib-based combination therapy for the treatment of patients with RRMM in real life. A total of 45 patients with RRMM from the Bursa Uludağ University Faculty of Medicine Department of Hematology were included in the study retrospectively. The median follow-up time was 15.9 months. The median age was 66 40-84. 8.8 of patients were ranked 2nd, 15.5 were ranked 3rd, 35.5 were ranked 4th, and 40 were 5th took ixazomib. Overall, 100 of patients were on PIs bortezomib 100, carfilzomib 31.1, 88.8 on immunomodulatory drugs IMID lenalidomide 86.6, pomalidomide 33.3, thalidomide 4.4 and 55.5 also underwent autologous stem cell transplantation before the combination of ixazomib, lenalidomide, and dexamethasone IRd. All patients received ixazomib in combination with lenalidomide and dexamethasone. The treatment was well tolerated, with a low discontinuation rate due to adverse events 6.6. The most common side effects were cytopenia 50 and infection 25. The overall response rate was 77.7, the very good partial response rate was 20, the complete response rate was 28, the partial response rate was 11.4, the minimal response rate was 5.7, the stable disease rate was 5.7, and progressive disease rate was 28.5. Median progression-free survival PFS on ixazomib treatment was 29.1 months 95 CI 17.2-40.9. PFS was 75 and 59 at 12 and 24 months, respectively. Median overall survival OS was 22.6 months 95 CI 18.8-30.3.; OS was 73 and 49 at 12 and 24 months, respectively. IRd is an effective, safe, and easy-to-administer regimen in real-life RRMM patients because it can be administered orally.

 İlk oral proteazom inhibitörü PI olan iksazomib, lenalidomid ve deksametazon IRd ile kombinasyon halinde relaps refrakter multipl miyelomun RRMM tedavisi için onaylanmıştır. Bununla birlikte, klinik çalışma sonuçları her zaman gerçek dünyadaki sonuçlarla örtüşmez. Bu çalışmanın amacı, gerçek yaşamda RRMMli hastaların tedavisi için iksazomib bazlı kombinasyon tedavisinin sonuçlarını değerlendirmektir. Çalışmaya Bursa Uludağ Üniversitesi Tıp Fakültesi Hematoloji Bilim Dalından toplam 45 RRMM tanılı hasta retrospektif olarak dahil edildi. Medyan takip süresi 15.9 ay 0.3-53.8 ve medyan yaş 66 40-84 idi. Hastaların 8.8i 2. sırada,  15.5i 3. sırada, 35.5i 4. sırada ve 40ı da 5. sırada iksazomib aldı. Genel olarak, IRdden önce hastaların 100ü PI bortezomib 100, karfilzomib 31.1, 88.8i immünomodülatör ilaç IMID lenalidomid 86.6, pomalidomid 33.3, talidomid 4.4 almış ve 55.5ine de otolog kök hücre nakli yapılmıştır. Hastaların hepsi lenalidomid ve deksametazon ile kombinasyon halinde iksazomib almıştır. Tedavi, yan etki nedenli düşük bir kesilme oranıyla 6.6 iyi tolere edilmiştir. En sık görülen yan etkiler sitopeni 50 ve enfeksiyon 25 olmuştur. Genel yanıt oranı 77.7, çok iyi kısmi yanıt oranı 20, tam yanıt oranı  28,5 kısmi yanıt oranı 11.4, minimal yanıt oranı 5.7, stabil hastalık oranı 5.7, progresif hastalık oranı 28.5 saptandı. İksazomib tedavisinde medyan progresyonsuz sağkalım PFS 29.1 aydı 95 GA 17.240.9. PFS 12 ve 24 ayda sırasıyla 75 ve 59 idi. Medyan genel sağkalım OS 22.6ay 95 GA 18.840.9 idi; OS 12 ve 24 ayda sırasıyla 73 ve 49 idi. Gerçek yaşamda RRMM hastalarında IRd etkili, güvenli ve oral verilebilmesi nedeniyle kolay uygulanabilir bir rejimdir.

Makale detayları

Combination Experience of Ixazomib, Lenalidomide, Dexamethasone in Relapsed Refractory Multiple Myeloma: Real-Life Data

Yazarlar:

Tuba Ersal | Vildan Ozkocaman | Cumali Yalçın | Bedrettin Orhan | Ömer Candar | Sinem Çubukçu | Tuba Güllü Koca | Fazıl Cagrı Hunutlu | Şeyma Yavuz | İbrahim Ethem Pınar | Rıdvan Ali | Fahir Özkalemkaş

Yayıncı:

Bursa Uludağ University

Ana Başlıklar:

Hematoloji

Dergi:

Uludağ Üniversitesi Tıp Fakültesi Dergisi Vol.49 Issue 1, pp.95-99

Belge Tipi:

Makale

Yayın Tarihi:

9/2023

Belge Dili:

Türkçe

Document ID (Org No.):

2001291066

pISSN:

1300-414X

Myelom

Relaps

Refrakter

İksazomibMyelom

Relaps

Refrakter

İksazomib

Sayı

Makale detayları

Yazarlar: Tuba Ersal | Vildan Ozkocaman | Cumali Yalçın | Bedrettin Orhan | Ömer Candar | Sinem Çubukçu | Tuba Güllü Koca | Fazıl Cagrı Hunutlu | Şeyma Yavuz | İbrahim Ethem Pınar | Rıdvan Ali | Fahir Özkalemkaş

Yayıncı: Bursa Uludağ University

Ana Başlıklar: Hematoloji

Dergi: Uludağ Üniversitesi Tıp Fakültesi Dergisi Vol.49 Issue 1, pp.95-99

Belge Tipi: Makale

Yayın Tarihi: 9/2023

Belge Dili: Türkçe

Document ID (Org No.): 2001291066

pISSN: 1300-414X

Sayı

Yazarlar:

Tuba Ersal | Vildan Ozkocaman | Cumali Yalçın | Bedrettin Orhan | Ömer Candar | Sinem Çubukçu | Tuba Güllü Koca | Fazıl Cagrı Hunutlu | Şeyma Yavuz | İbrahim Ethem Pınar | Rıdvan Ali | Fahir Özkalemkaş

Yayıncı:

Bursa Uludağ University

Ana Başlıklar:

Hematoloji

Dergi:

Uludağ Üniversitesi Tıp Fakültesi Dergisi Vol.49 Issue 1, pp.95-99

Belge Tipi:

Makale

Yayın Tarihi:

9/2023

Belge Dili:

Türkçe

Document ID (Org No.):

2001291066

pISSN:

1300-414X